TABLE 1.
Patient, Donor, and Transplant Characteristics
| All Patients | Patients in CR | Patients in CRp | Patients in MLFS | P value | |
|---|---|---|---|---|---|
| Number of patients (%) | 270 | 206 (76%) | 45 (17%) | 19 (7%) | |
| Median patient age, yr (range) |
54 (17–74) | 53 (17–72) | 58 (21–74) | 57 (24–73) | 0.085 |
| Patient sex (%) | |||||
| Female | 124 (46) | 101 (49) | 18 (40) | 5 (26) | 0.112 |
| Male | 146 (54) | 105 (51) | 27 (60) | 14 (74) | |
| Donor sex (%) | |||||
| Female | 93 (34) | 71 (34) | 13 (29) | 9 (47) | 0.364 |
| Male | 177 (66) | 135 (66) | 32 (71) | 10 (53) | |
| Donor-Patient sex (%) | |||||
| Female-Male | 44 (16) | 29 (14) | 7 (16) | 8 (42) | 0.007 |
| Other | 226 (84) | 177 (86) | 38 (84) | 11 (58) | |
| Disease etiology (%) | |||||
| De novo | 212 (79) | 166 (81) | 31 (69) | 15 (79) | 0.228 |
| Secondary | 37 (14) | 25 (12) | 8 (18) | 4 (21) | |
| Therapy related | 21 (7) | 15 (7) | 6 (13) | 0 (0) | |
| Disease classification by cytogenetics (%) |
|||||
| Favorable | 26 (10) | 21 (10) | 3 (7) | 2 (11) | 0.392 |
| Intermediate | 163 (60) | 123 (60) | 26 (58) | 14 (73) | |
| Poor | 77 (29) | 59 (29) | 16 (35) | 2 (11) | |
| Unknown | 4 (1) | 3 (1) | 0 (0) | 1 (5) | |
| Time from last chemotherapy to transplant, days (range) |
62 (16–366) | 61 (16–366) | 76 (66–198) | 61 (20–273) | 0.079 |
| Pre-transplant bone marrow cellularity ≤ 10% (%) |
37 (14) | 18 (8.7) | 10 (22) | 9 (47) | <0.001 |
| Persistent cytogenetic and/or molecular abnormalities on pre- transplant bone marrow (%) |
37/244 (15) | 24/183 (13) | 7/42 (17) | 6/19 (32) | <0.001 |
| HCT-CI score (%) | |||||
| Low risk | 28 (11) | 26 (13) | 1 (3) | 1 (5) | 0.024 |
| Intermediate risk | 47 (17) | 37 (18) | 6 (13) | 4 (21) | |
| High risk | 195 (72) | 143 (69) | 38 (84) | 14 (74) | |
| Conditioning regimen (%) | |||||
| MA | 193 (72) | 155 (76) | 25 (56) | 13 (68) | 0.024 |
| RIC | 76 (28) | 50 (24) | 20 (44) | 6 (32) | |
| Unknown | 1 (0) | 1 (0) | 0 (0) | 0 (0) | |
| ATG regimen (%) | |||||
| No | 206 (76) | 160 (78) | 31 (69) | 15 (79) | 0.437 |
| Yes | 64 (24) | 46 (22) | 14 (31) | 4 (21) | |
| Transplant type (%) | |||||
| MRD | 104 (39) | 78 (38) | 18 (40) | 8 (42) | 0.913 |
| MUD | 166 (61) | 128 (62) | 27 (60) | 11 (58) | |
| Stem cell source (%) | |||||
| Peripheral blood | 254 (94) | 191 (93) | 45 (100) | 18 (95) | 0.195 |
| Bone marrow | 15 (6) | 14 (7) | 0 (0) | 1 (5) | |
| Immune prophylaxis (%) | |||||
| MTX, MMF, tacrolimus | 33 (12) | 23 (11) | 8 (18) | 2 (11) | 0.801 |
| MTX, tacrolimus | 213 (79) | 165 (80) | 33 (73) | 15 (78) | |
| Other1 | 24 (9) | 18 (9) | 4 (9) | 2 (11) | |
| CMV Reactivation (%) | |||||
| Yes | 134 (50) | 97 (47) | 24 (53) | 13 (68) | 0.118 |
| No | 136 (50) | 109 (53) | 21 (47) | 6 (32) | |
MRD, matched related donor; MUD, matched unrelated donor; MA, myeloablative; RIC, reduced intensity and non-myeloablative; ATG, anti-thymocyte globulin; MTX, methotrexate; MMF, mycophenolate mofetil.
1
Other includes cyclosporine and sirolimus.